Here's Gregg Alton, a vice president of drug maker Gilead, on whether they'll cut the price of their $1000-a-day Hep C pill after it recoups their investment: "That's very unlikely that we would do that. I appreciate the thought." [NPR]

Continue the discussion at bbs.boingboing.net

57 replies